News
- Author:
- Bruce Jancin
Publish date: November 13, 2019
COPENHAGEN – “Anybody who deals with bipolar patients knows that sleep is a constant issue.”
News
- Author:
- Bruce Jancin
Publish date: November 12, 2019
COPENHAGEN – “There are some effects on insomnia when you treat depression, but they’re not very large.”
News
- Author:
- Bruce Jancin
Publish date: November 12, 2019
COPENHAGEN – Oral drug with multimodal actions is also under study for other disorders.
News
- Author:
- Bruce Jancin
Publish date: November 12, 2019
COPENHAGEN – “The main finding of the study ... is that we found no major differences in physiology between male and female conduct disorder.”
News
- Author:
- Bruce Jancin
Publish date: November 10, 2019
COPENHAGEN – Psychedelic microdosing is trendy – but is it really an effective performance enhancer?
News
- Author:
- Bruce Jancin
Publish date: November 7, 2019
MADRID – A host of Janus kinsase inhibitors are in the developmental pipeline for this psychosocially devastating disease, for which at present the...
News
- Author:
- Bruce Jancin
Publish date: November 6, 2019
MADRID – “We saw onset of pruritus improvement in week 1 and onset of lesion healing at week 4.”
Article
- Author:
- Bruce Jancin
Publish date: November 6, 2019
SAN ANTONIO – Largest-ever meta-analysis shows 43% relative risk reduction in HCC.
News
- Author:
- Bruce Jancin
Publish date: November 5, 2019
SAN ANTONIO – One audience member leapt to his feet to declare: “This is the study we’ve all been waiting for.”
News
- Author:
- Bruce Jancin
Publish date: November 1, 2019
PARIS – Prescient childhood cohort studies launched in the 1970s are paying off.
News
- Author:
- Bruce Jancin
Publish date: November 1, 2019
SAN ANTONIO – First U.S. phase 3 trial for eosinophilic esophagitis hits all endpoints.
News
- Author:
- Bruce Jancin
Publish date: October 30, 2019
PARIS – Five-year overall survival ranged from 81% to 23% in concert with PAD patients’ Geriatric Nutritional Ris...
News
- Author:
- Bruce Jancin
Publish date: October 29, 2019
MADRID – Ruxolitinib cream, a topical JAK 1/2 inhibitor, achieved unprecedented improvement in facial and total-body vitiligo.
News
- Author:
- Bruce Jancin
Publish date: October 29, 2019
MADRID – “We really think that older patients should be offered treatments at the same level of disease control as all the rest of our psoriasis pa...
News
- Author:
- Bruce Jancin
Publish date: October 28, 2019
COPENHAGEN – “I think it is very important to understand that we need to screen pregnant women for sleep problems.” – Tiina Paunio, MD, PhD
